( 60 percent) are important. Fifty-five percent believe that it is possible to improve
quality and reduce costs simultaneously
in the current system of care, while 23
percent agree that increased privatization
in the healthcare system would improve
the system’s performance. A total of 50
percent are uncertain and 27 percent disagree.
C.R. Bard Inks Deal for Ireland-
Based Provider of Catheter Tech
C.R. Bard Inc. has offered to acquire Wex-
ISO 9001:2000 ISO 13485:2003 AS 9100 B
MEETING YOUR NEEDS FOR PRECISION STAINLESS STEEL
ford, Ireland-based Clearstream Technologies Group plc, an Irish developer of
catheters used in angioplasty procedures,
for about $68.5 million.
Murray Hill, N.J.-based Bard will pay 85
pence per share, or $1.33, for all outstanding shares of Clearstream’s stock, an 85
percent premium on its closing price of
45. 89 pence per share on the London
“The acquisition of Clearstream represents a compelling strategic opportunity for Bard, enabling us to strengthen
our leadership in vascular medical devices,” said C.R. Bard Chairman and CEO
Bard derives a little less than a third of
its total sales from its vascular business,
which produces catheters and stents for peripheral vascular disease and heart arrhythmias. In the first half of 2011, its vascular
business jumped 15 percent to $413 million
compared with the first half of 2010.
• Extensive inventory of Tubing, Bar Stock, Hollow Bar, Flanges, Pipe, Fittings • Cut-to-length stainless tubing • CNC machined stainless parts • Bending and coiling of stainless and other materials • Redrawing of stainless tubing,
rod and bar stock
EAGLE STAINLESS Tube & Fabrication Inc.
Johnson & Johnson Wants to
10 Discovery Way Franklin Massachusetts
phone 800-528-8650 fax. 800-520-1954
Explore New Product Areas;
Ethicon Buys SterilMed
Johnson & Johnson has had a roller coaster
of a year. Product recalls in consumer,
pharmaceuticals and device product lines
have challenged the venerable brand’s
capacity to rebound. But come back it
will—with market leading new technology,
according to company executives.
For example, the company is looking to
add heart valves and pumps to its product
lineup as it reshapes its medical device
portfolio. Chief Financial Officer Dominic
Caruso indicated that J&J sees other attractive technologies in the cardiac device market, and could enter those sectors either
through the acquisition of another company or by organically developing products.
Heart valves and left ventricular assist devices—pumps implanted in patients with
advanced heart failure who are awaiting a
transplant—are two such opportunities.
“Both are interesting,”Caruso said at an
investor conference on Sept. 13.“We are in-
terested in looking at them.”
J&J announced its plans to stop selling
drug-coated heart stents in June, citing the